Navigation Links
University of Ottawa Heart Institute Trial Finds Popular Blood Clotting Drug Does Not Improve Patient Outcomes and Increases Risk of Bleeding

WASHINGTON, Oct. 15 /PRNewswire/ - A popular drug used to prevent blood clotting during the treatment of severe heart attacks does not improve outcomes for patients undergoing a life-saving surgical procedure. Further, the drug - known generically as eptifibatide (pronounced ep-ti-fy-bah-tide) - also increases the risk of bleeding. The results follow a ground-breaking clinical trial conducted at the University of Ottawa Heart Institute (UOHI) which sought to determine the efficacy of a drug that is widely used but for which little clinical evidence was available to indicate a positive impact on treatment.

The three-year trial, called ASSIST, was designed to test the safety and efficacy of eptifibatide in serious heart attack patients who underwent an emergency angioplasty - called primary PCI - to open blood and oxygen flow to the heart. The study involved a total of 400 patients diagnosed with ST-Segment Elevation Myocardial Infarction (STEMI) at UOHI; 200 undergoing primary PCI using eptifibatide, and 200 who did not. The Heart Institute's trial results showed that using eptifibatide did not significantly improve patient outcomes. In fact, the study found that using the drug increased the risk of bleeding.

"We believe there is no supporting evidence to be incorporating this drug therapy for the treatment of acute STEMI patients, said Dr. Michel Le May, Director, Coronary Care Unit

Research Group, UOHI. "In fact, there is increased risk associated with its use. As a result, we expect this study will reshape our current clinical practice of medicine in managing the treatment and care of heart attack patients."

Dr. Le May presented the findings of the ASSIST trial today in Washington, D.C. at the 2008 Transcatheter Cardiovascular Therapeutics (TCT) Symposium, where interventional cardiologists from around the world gather to discuss innovative techniques and therapies in cardiovascular medicine.

About UOHI

The University of Ottawa Heart Institute is Canada's largest and foremost cardiovascular health centre dedicated to understanding, treating and preventing heart disease. We deliver high-tech care with a personal touch, shape the way cardiovascular medicine is practiced, and revolutionize cardiac treatment and understanding. We build knowledge through research and translate discoveries into advanced care. We serve the local, national and international community, and are pioneering a new era in heart health. For more information, visit

/NOTE TO PHOTO EDITORS: A photo accompanying this release is available on

the CNW Photo Network and archived at

Additional archived images are also available on the CNW Photo Archive

website at Images are free to accredited

members of the media/

SOURCE Ottawa Heart Institute, University of Ottawa
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Stanford University Rises to Top of 2008 Trojan(R) Sexual Health Report Card
2. LodgeNet Healthcare Signs New Agreement with NorthShore University HealthSystem
3. The Lanier Law Firm Announces Wrongful Death Lawsuit Against Rice University, Former Coach, NCAA, Others in Students Sickle-Cell Death
4. AARP: Cornell University Tops 2008 List of Best Employers for Workers Over 50
5. Staten Island University Hospital to Pay the U.S. $74 Million to Settle Claims of Defrauding Federal Health Care Programs
6. University of Washington School of Social Work and Partners for Our Children Awarded Top National Recognition
7. Harvard University recipient of Global Health Nutrition grant
8. Mayo Clinic, McMaster University Research Review Shows Internet-based Instruction Effective for Teaching Health Care Professionals
9. Delft University of Technology patent for manufacturing radio isotopes
10. University Physicians Healthcare (UPH) Selects Broadlane to Provide Comprehensive Supply Chain Services
11. PAs Smoking Ban Should Filter Into Homes and Cars Too, According to Temple University Expert
Post Your Comments:
(Date:11/28/2015)... ... , ... Safe storage for contraceptive devices may not always be easy to ... and the other from Bradley Beach, New Jersey, there is an easy solution to ... to replace NuvaRings more often than necessary. As such, it affords peace of mind ...
(Date:11/27/2015)... ... November 28, 2015 , ... There is only one major question facing ... last year? , This question has not been an easy question to answer. Especially ... age and the younger workforce don’t share the same discipline around working long hours. ...
(Date:11/27/2015)... ... 27, 2015 , ... The rapid speed at which Americans ... more care is needed, especially with Alzheimer’s, dementia and other cognitive conditions becoming ... The forgotten part of this equation: 80 percent of medical care occurs in ...
(Date:11/27/2015)... ... 27, 2015 , ... Lizzie’s Lice Pickers just announced a special promotion that ... of their purchase of lice treatment product. In addition, customers will receive a complimentary ... spokesperson. “Finding lice is a sure way to ruin the holidays, so we encourage ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... of progress through sharing, the 2016 Building Better Radiology Marketing Programs ... will begin on Sunday, March 6, 2016, at Caesars Palace in Las Vegas ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ... the "2016 Future Horizons and Growth Strategies ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> --> This ... the Italian therapeutic drug monitoring market, including emerging ...
(Date:11/25/2015)... , Nov. 25, 2015  Amgen (NASDAQ: AMGN ... Application (BLA) with the United States ... 501, a biosimilar candidate to Humira ® (adalimumab). ... application submitted to the FDA and represents Amgen,s first ... Sean E. Harper , M.D., executive vice president of ...
(Date:11/25/2015)... Nov. 25, 2015  ARKRAY USA ... to provide evidence demonstrating the accuracy of its blood ... on Insulin Resistance, Diabetes and Cardiovascular Disease in ... the Company,s GLUCOCARD ® 01 meter and the ... requirements. The ability to accurately measure glucose levels in ...
Breaking Medicine Technology: